Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 7/20 | 0.37 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18820485 | 0.86 | CCR1 (0.40) | MTNR1AMTNR1BCCR1RAB9ACCR5 | |
| SCHEMBL14960978 | 0.85 | HTR2A (0.51) | MPOHTR2AHTR1DHTR1AHTR1B | |
| SCHEMBL14961090 | 0.82 | MPO (0.52) | MTNR1AMTNR1BMPOHTR2AHTR1D | |
| SCHEMBL23535555 | 0.81 | MTNR1A (0.40) | MTNR1AMTNR1BMPOHTR2AHTR1D | |
| SCHEMBL29920103 | 0.81 | MTNR1A (0.40) | MTNR1AMTNR1BMPOHTR2AHTR1D | |
| SCHEMBL14961107 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BMPOHTR2AHTR1D | |
| SCHEMBL22643887 | 0.79 | MTNR1A (0.39) | MTNR1AMTNR1BMPOHTR2AHTR1D | |
| SCHEMBL19701183 | 0.78 | CCR1 (0.36) | MTNR1AMTNR1BCCR1RAB9ACCR5 | |
| SCHEMBL12565429 | 0.78 | ADORA2A (0.40) | MTNR1AMTNR1BCCR1RAB9ACCR5 | |
| SCHEMBL19701184 | 0.78 | ALDH1A1 (0.47) | MTNR1AMTNR1BCCR1RAB9ACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | MTNR1A 570/4885MTNR1B 782/4885CCR1 1332/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | MTNR1A 570/4885MTNR1B 782/4885CCR1 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.